# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0001493152-25-009782
Filing Date
2025-03-11
Accepted
2025-03-11 08:00:32
Documents
16
Period of Report
2025-03-10
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 |  | form8-k.htm iXBRL | 8-K | 41769
2 |  | ex99-1.htm | EX-99.1 | 14923
3 |  | ex99-1_001.jpg | GRAPHIC | 853371
| Complete submission text file | 0001493152-25-009782.txt |  | 1457526

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL SCHEMA FILE | lixt-20250310.xsd | EX-101.SCH | 3519
5 | XBRL DEFINITION FILE | lixt-20250310_def.xml | EX-101.DEF | 29971
6 | XBRL LABEL FILE | lixt-20250310_lab.xml | EX-101.LAB | 36548
7 | XBRL PRESENTATION FILE | lixt-20250310_pre.xml | EX-101.PRE | 26994
18 | EXTRACTED XBRL INSTANCE DOCUMENT | form8-k_htm.xml | XML | 5517

Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 25725893
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)